Patents by Inventor Jason Damiano
Jason Damiano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210155697Abstract: The invention relates to anti-Tie2 antibodies and methods of using the same.Type: ApplicationFiled: November 19, 2020Publication date: May 27, 2021Inventors: Jason Damiano, Kristina Oresic Bender, Richard Theolis, Deepika Bhatnagar, Nina Ly
-
Patent number: 10626172Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: May 24, 2018Date of Patent: April 21, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20190194315Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: June 17, 2016Publication date: June 27, 2019Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Publication number: 20190119375Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: May 24, 2018Publication date: April 25, 2019Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Patent number: 10005836Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: November 13, 2015Date of Patent: June 26, 2018Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20160137730Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: November 13, 2015Publication date: May 19, 2016Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20150175705Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: March 3, 2015Publication date: June 25, 2015Inventors: Jason Damiano, Mohammad Luqman, Linda Masat, Amer Mirza, Genevieve Nonet, Daniel Bedinger
-
Patent number: 9005614Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: November 22, 2010Date of Patent: April 14, 2015Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Publication number: 20110150760Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: November 22, 2010Publication date: June 23, 2011Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
-
Patent number: 7867493Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: August 17, 2007Date of Patent: January 11, 2011Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Publication number: 20080292620Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: August 17, 2007Publication date: November 27, 2008Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Publication number: 20080051346Abstract: Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3) or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.Type: ApplicationFiled: March 30, 2007Publication date: February 28, 2008Inventors: William Dalton, Jason Damiano, Anne Cress
-
Publication number: 20070184480Abstract: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.Type: ApplicationFiled: March 26, 2007Publication date: August 9, 2007Applicant: The Burnham InstituteInventors: John Reed, Frederick Pio, Adam Godzik, Christian Stehlik, Jason Damiano, Sug Lee, Vasco Oliveira, Hideki Hayashi, Kryzysztof Pawlowski
-
Publication number: 20050113305Abstract: Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3) or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.Type: ApplicationFiled: October 29, 2004Publication date: May 26, 2005Inventors: William Dalton, Jason Damiano, Anne Cress
-
Publication number: 20050037378Abstract: The invention provides a polypeptide corresponding to a newly identified splice variant of the CARD3X gene, termed CARD3X-2. Also provided by the invention is an encoding nucleic acid molecule, as well as a CARD3X-2 specific antibody. The invention further provides related screening, diagnostic and therapeutic methods.Type: ApplicationFiled: January 27, 2004Publication date: February 17, 2005Inventors: John Reed, Frederick Pio, Adam Godzik, Christian Stehlik, Jason Damiano, Sug Lee, Vasco Oliveira, Hideki Hayashi, Kryzysztof Pawlowski